Not yet reviewed — this article is pending editorial review by Lyrea.

25iP-NBOMe

N-(2-Methoxybenzyl)-4-isopropyl-2,5-dimethoxyphenethylamine

2C-iP-NBOMe, NBOMe-2C-iP

Psychoactive Class

Psychedelic Hallucinogen

Chemical Class

Phenethylamine (N-benzylated)NBOMe

25iP-NBOMe is a synthetic psychedelic of the substituted phenethylamine class, specifically an N-benzylated derivative of the hallucinogen 2C-iP. It has emerged as a rarely encountered novel designer drug¹ and remains largely unresearched. Reported to be extremely potent with stimulating qualities, it may produce uncomfortable body load and potentially dangerous vasoconstriction at higher doses. Very limited information is available regarding its safety profile and pharmacological properties.

Dosage & Duration

Dosage

Threshold~250 µg

Light300-750 µg

Moderate750-1000 µg

Strong1000-1500 µg

Heavy1500+ µg

Duration

Onset30-60 minutes

After Effects1-12 hours

Total5-7 hours

Subjective Effects

25iP-NBOMe produces a stimulating psychedelic experience broadly typical of the NBOMe series, combining euphoria, empathy, and a sense of insight with prominent open and closed-eye visuals. The headspace involves a general shift in perception and a softening of the ego, though confusion can also occur. As with other N-benzylphenethylamines, the substance is active at sub-milligram doses and its subjective profile remains only sparsely documented.

Physical

The body experience carries a distinct stimulation with restlessness, muscle tension, and decreased appetite. Pupil dilation, sweating and chills, and difficulty sleeping are also reported.

Stimulation

Restlessness

Uncomfortable

Appetite suppression Pupil dilation Muscle tension

Cognitive

The mental state is stimulating and euphoric, with enhanced empathy, a sense of insight, and a mild softening of the sense of self. Confusion is possible, particularly at stronger doses.

Confusion

Emotional

Euphoria Empathy enhancement

Visual

Visual effects include brightened colors and both open and closed-eye visuals.

Tactile

Sense of touch is enhanced.

Tactile enhancement

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)

Mecke(ME)

Mandelin(MD)

Liebermann(LB)

PROtestkit.eu

Pharmacology

Pharmacodynamics

25iP-NBOMe produced off-target μ-opioid receptor activation in two cell-based assay systems, but the result was weak in the receptor-proximal β-arrestin-2 assay: about 6% of the hydromorphone reference response at 100 μM, without a plateau from which a reliable EC50 could be calculated.²

Its apparently high response in the calcium-release assay was accompanied by the strongest non-MOR-mediated signal among the tested analogues, so that response cannot be treated as clean μ-opioid receptor efficacy.²

Because μ-opioid activity in this series occurred only at high concentrations, the investigators considered clinically relevant opioid toxicity from this mechanism unlikely at physiologically relevant concentrations.²

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AMTLithiumPregabalin

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

AmphetaminesCocaineDXMTramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE

TripSit

Tolerance

Cross Tolerance

Serotonergic psychedelics, 5-HT2A agonists

Harm Potential

Toxicity

Cardiovascular

May cause potentially dangerous vasoconstriction at high doses; the extreme potency of this compound increases the risk of accidental overdose leading to cardiovascular complications.

History & Culture

25iP-NBOMe emerged as a novel designer drug and was first documented in the scientific literature around 2014. Like other members of the NBOMe series, it represents an N-benzyl modification of an existing 2C-x compound—in this case, 2C-iP. The substance remains relatively obscure compared to more widely encountered NBOMe compounds such as 25I-NBOMe or 25C-NBOMe,¹ with limited information available regarding its history of human use or cultural significance.

Legality

International

The 2025 Green List separately lists 25I-NBOMe in 1971 Convention Schedule I as 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine. That is not 25iP-NBOMe and does not establish structural coverage of 25iP-NBOMe. Complete current 1961, 1971, and 1988 INCB lists were inspected before reaching this absence finding.

By Country

CanadaIllegalSchedule III

Controlled Drugs and Substances Act, Schedule III, item 35³

25iP-NBOMe falls within Schedule III item 35's structural definition for 2C-phenethylamines. The definition covers a 2,5-dialkoxy phenethylamine with further benzene-ring substitution and an amino-group benzyl substitution, which encompasses the 2C-iP-NBOMe structure.

UkraineIllegalTable I · List 2

Cabinet of Ministers Resolution No. 770, Table I, List No. 2 (as amended by Resolution No. 600)⁷⁸

25IP-NBOMe (2C-IP-NBOMe) is expressly listed in Table I, List No. 2 of Ukraine’s controlled-substances list, together with its chemical name. List No. 2 is headed ‘Especially dangerous psychotropic substances, circulation of which is prohibited,’ so the substance’s circulation is prohibited. Resolution No. 600 adds this entry to List No. 2; the amendment takes effect on 23 July 2019 and remains present in the current consolidated list.

GermanyIllegal (analog/blanket ban)NpSG phenethylamine group

Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1; § 3⁴⁵⁶

25iP-NBOMe is covered as a derivative of 2-phenethylamine under Annex 1 no. 1 of the NpSG: its substituted phenyl ring and N-(2-methoxybenzyl) group fit the listed modular structure. The NpSG defines a substance in an Annex 1 group as a new psychoactive substance and prohibits its manufacture, trade, supply, import/export, acquisition, possession, and administration, subject to stated exceptions.

United KingdomIllegalClass A

Misuse of Drugs Act 1971, Schedule 2, Part I, paragraph 1(f), as inserted by the Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014⁹¹⁰¹¹

Controlled under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause, which covers NBOMe compounds as a structural class.¹² Class A substances carry the most severe penalties, with possession punishable by up to 7 years imprisonment and supply by up to life imprisonment.¹¹

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 25iP-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.